NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026
KEY FINDINGS
The North America botanical and plant derivative drug market is predicted to expand at a CAGR of 7.57%, for the forecast period of 2018-2026.
MARKET INSIGHTS
Several noted vendors in North America are increasingly promoting the deployment of botanical drugs and products as key dietary supplements. However, only a few products have been approved by the United States Food and Drug Administration (FDA) for deployment as prescription drugs. The increasing approval by FDA for botanical drugs and their escalating usage in the regions are presenting the market with potential growth opportunities.
COMPETITIVE INSIGHTS
Some of the major players in the market are Glenmark Pharmaceuticals Ltd, Bayer Healthcare Llc, Analyticon Discovery Gmbh, Piramal Phytocare Ltd, GlaxoSmithKline, Abbott Laboratories, Bionova, Tasly Pharmaceuticals Inc, Eli Lilly And Company, Medigene, Novartis International Ag, Boehringer Ingelheim, and Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd).
The North America botanical and plant derivative drug market is predicted to expand at a CAGR of 7.57%, for the forecast period of 2018-2026.
MARKET INSIGHTS
Several noted vendors in North America are increasingly promoting the deployment of botanical drugs and products as key dietary supplements. However, only a few products have been approved by the United States Food and Drug Administration (FDA) for deployment as prescription drugs. The increasing approval by FDA for botanical drugs and their escalating usage in the regions are presenting the market with potential growth opportunities.
COMPETITIVE INSIGHTS
Some of the major players in the market are Glenmark Pharmaceuticals Ltd, Bayer Healthcare Llc, Analyticon Discovery Gmbh, Piramal Phytocare Ltd, GlaxoSmithKline, Abbott Laboratories, Bionova, Tasly Pharmaceuticals Inc, Eli Lilly And Company, Medigene, Novartis International Ag, Boehringer Ingelheim, and Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd).
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. GLYCOSIDES IS QUICKLY RISING MARKET IN TERMS OF TYPES
3.2.2. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.3. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT DEMAND IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2018-2026
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2018-2026
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2018-2026
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. ANALYTICON DISCOVERY GMBH
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC INITIATIVE
9.2.4. SCOT ANALYSIS
9.3. BAYER HEALTHCARE LLC
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BOEHRINGER INGELHEIM
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVE
9.4.4. SCOT ANALYSIS
9.5. BIONOVA
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. BRISTOL-MYERS SQUIBB
9.6.1. OVERVIEW
9.6.2. STRATEGIC INITIATIVE
9.6.3. SCOT ANALYSIS
9.7. CURA PHARM
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.8. DR. WILLMAR SCHWABE GMBH & CO. KG
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. ELI LILLY AND COMPANY
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. GLAXOSMITHKLINE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. GLENMARK PHARMACEUTICALS LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVE
9.11.4. SCOT ANALYSIS
9.12. INDENA VIALE ORTLES
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. LUPIN LTD
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. MEDIGENE
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. NOVARTIS INTERNATIONAL AG
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. SCOT ANALYSIS
9.16. PFIZER
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVE
9.16.4. SCOT ANALYSIS
9.17. PIRAMAL PHYTOCARE LTD.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVE
9.17.4. SCOT ANALYSIS
9.18. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.18.1. OVERVIEW
9.18.2. PRODUCTION PORTFOLIO
9.18.3. STRATEGIC INITIATIVE
9.18.4. SCOT ANALYSIS
9.19. SANOFI
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. STRATEGIC INITIATIVE
9.19.4. SCOT ANALYSIS
9.20. TASLY PHARMACEUTICALS INC
9.20.1. OVERVIEW
9.20.2. PRODUCTION PORTFOLIO
9.20.3. SCOT ANALYSIS
TABLE LIST
TABLE 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2018-2026 ($ MILLION)
TABLE 2 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2018-2026 ($ MILLION)
TABLE 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2018-2026 ($ MILLION)
TABLE 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2018-2026 ($ MILLION)
TABLE 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET, BY PRODUCT 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2018-2026 ($ MILLION)
TABLE 16 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2018-2026 ($ MILLION)
TABLE 17 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2018-2026 ($ MILLION)
TABLE 18 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2018-2026 ($ MILLION)
TABLE 19 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2018-2026 ($ MILLION)
TABLE 22 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2018-2026 ($ MILLION)
FIGURE 2 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2018-2026 ($ MILLION)
FIGURE 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2018-2026 ($ MILLION)
FIGURE 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2018-2026 ($ MILLION)
FIGURE 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2018-2026 ($ MILLION)
FIGURE 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2018-2026 ($ MILLION)
FIGURE 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2018-2026 ($ MILLION)
FIGURE 8 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2018-2026 ($ MILLION)
FIGURE 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2018-2026 ($ MILLION)
FIGURE 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2018-2026 ($ MILLION)
FIGURE 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
FIGURE 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2018-2026 ($ MILLION)
FIGURE 13 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2018-2026 ($ MILLION)
FIGURE 14 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2018-2026 ($ MILLION)
FIGURE 15 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2018-2026 ($ MILLION)
FIGURE 16 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2018-2026 ($ MILLION)
FIGURE 17 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2018-2026 ($ MILLION)
FIGURE 18 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2018-2026 ($ MILLION)
FIGURE 19 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
FIGURE 20 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 21 UNITED STATES BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 22 CANADA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 23 BOTANICAL & PLANT DERIVATIVE DRUG MARKET SHARE 2016
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. ANALYTICON DISCOVERY GMBH
3. BAYER HEALTHCARE LLC
4. BOEHRINGER INGELHEIM
5. BIONOVA
6. BRISTOL-MYERS SQUIBB
7. CURA PHARM
.8. DR. WILLMAR SCHWABE GMBH & CO. KG
9. ELI LILLY AND COMPANY
10. GLAXOSMITHKLINE
11. GLENMARK PHARMACEUTICALS LTD.
12. INDENA VIALE ORTLES
13. LUPIN LTD
14. MEDIGENE
15. NOVARTIS INTERNATIONAL AG
16. PFIZER
17. PIRAMAL PHYTOCARE LTD.
18. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
19. SANOFI
20. TASLY PHARMACEUTICALS INC.
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. GLYCOSIDES IS QUICKLY RISING MARKET IN TERMS OF TYPES
3.2.2. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.3. HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT DEMAND IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2018-2026
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2018-2026
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2018-2026
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. ANALYTICON DISCOVERY GMBH
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. STRATEGIC INITIATIVE
9.2.4. SCOT ANALYSIS
9.3. BAYER HEALTHCARE LLC
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BOEHRINGER INGELHEIM
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. STRATEGIC INITIATIVE
9.4.4. SCOT ANALYSIS
9.5. BIONOVA
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. BRISTOL-MYERS SQUIBB
9.6.1. OVERVIEW
9.6.2. STRATEGIC INITIATIVE
9.6.3. SCOT ANALYSIS
9.7. CURA PHARM
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.8. DR. WILLMAR SCHWABE GMBH & CO. KG
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. ELI LILLY AND COMPANY
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.10. GLAXOSMITHKLINE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. GLENMARK PHARMACEUTICALS LTD.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVE
9.11.4. SCOT ANALYSIS
9.12. INDENA VIALE ORTLES
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. LUPIN LTD
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. MEDIGENE
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. NOVARTIS INTERNATIONAL AG
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. SCOT ANALYSIS
9.16. PFIZER
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVE
9.16.4. SCOT ANALYSIS
9.17. PIRAMAL PHYTOCARE LTD.
9.17.1. OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVE
9.17.4. SCOT ANALYSIS
9.18. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.18.1. OVERVIEW
9.18.2. PRODUCTION PORTFOLIO
9.18.3. STRATEGIC INITIATIVE
9.18.4. SCOT ANALYSIS
9.19. SANOFI
9.19.1. OVERVIEW
9.19.2. PRODUCT PORTFOLIO
9.19.3. STRATEGIC INITIATIVE
9.19.4. SCOT ANALYSIS
9.20. TASLY PHARMACEUTICALS INC
9.20.1. OVERVIEW
9.20.2. PRODUCTION PORTFOLIO
9.20.3. SCOT ANALYSIS
TABLE LIST
TABLE 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2018-2026 ($ MILLION)
TABLE 2 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2018-2026 ($ MILLION)
TABLE 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2018-2026 ($ MILLION)
TABLE 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2018-2026 ($ MILLION)
TABLE 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2018-2026 ($ MILLION)
TABLE 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2018-2026 ($ MILLION)
TABLE 8 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
TABLE 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2018-2026 ($ MILLION)
TABLE 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2018-2026 ($ MILLION)
TABLE 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2018-2026 ($ MILLION)
TABLE 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2018-2026 ($ MILLION)
TABLE 13 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
TABLE 14 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET, BY PRODUCT 2018-2026 ($ MILLION)
TABLE 15 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2018-2026 ($ MILLION)
TABLE 16 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2018-2026 ($ MILLION)
TABLE 17 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2018-2026 ($ MILLION)
TABLE 18 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2018-2026 ($ MILLION)
TABLE 19 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2018-2026 ($ MILLION)
TABLE 20 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2018-2026 ($ MILLION)
TABLE 21 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2018-2026 ($ MILLION)
TABLE 22 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE LIST
FIGURE 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2018-2026 ($ MILLION)
FIGURE 2 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2018-2026 ($ MILLION)
FIGURE 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2018-2026 ($ MILLION)
FIGURE 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2018-2026 ($ MILLION)
FIGURE 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2018-2026 ($ MILLION)
FIGURE 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2018-2026 ($ MILLION)
FIGURE 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2018-2026 ($ MILLION)
FIGURE 8 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2018-2026 ($ MILLION)
FIGURE 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2018-2026 ($ MILLION)
FIGURE 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2018-2026 ($ MILLION)
FIGURE 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2018-2026 ($ MILLION)
FIGURE 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2018-2026 ($ MILLION)
FIGURE 13 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2018-2026 ($ MILLION)
FIGURE 14 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2018-2026 ($ MILLION)
FIGURE 15 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2018-2026 ($ MILLION)
FIGURE 16 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2018-2026 ($ MILLION)
FIGURE 17 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2018-2026 ($ MILLION)
FIGURE 18 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2018-2026 ($ MILLION)
FIGURE 19 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
FIGURE 20 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 21 UNITED STATES BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 22 CANADA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2018-2026 ($ MILLION)
FIGURE 23 BOTANICAL & PLANT DERIVATIVE DRUG MARKET SHARE 2016
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. ANALYTICON DISCOVERY GMBH
3. BAYER HEALTHCARE LLC
4. BOEHRINGER INGELHEIM
5. BIONOVA
6. BRISTOL-MYERS SQUIBB
7. CURA PHARM
.8. DR. WILLMAR SCHWABE GMBH & CO. KG
9. ELI LILLY AND COMPANY
10. GLAXOSMITHKLINE
11. GLENMARK PHARMACEUTICALS LTD.
12. INDENA VIALE ORTLES
13. LUPIN LTD
14. MEDIGENE
15. NOVARTIS INTERNATIONAL AG
16. PFIZER
17. PIRAMAL PHYTOCARE LTD.
18. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
19. SANOFI
20. TASLY PHARMACEUTICALS INC.
